

Dated: May 15, 2012.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of  
Diversion Control, Drug Enforcement  
Administration.*

[FR Doc. 2012-12326 Filed 5-21-12; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice Of Application; Research Triangle Institute

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 12, 2012, Research Triangle Institute, Hermann Building, East Institute Drive, P.O. Box 12194, Research Triangle, North Carolina 27709, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Marihuana (7360) .....	I
Cocaine (9041) .....	II

The Institute will manufacture marihuana, and cocaine derivatives for use by their customers in analytical kits, reagents, and reference standards as directed by the National Institute on Drug Abuse.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than July 23, 2012.

Dated: May 15, 2012.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of  
Diversion Control, Drug Enforcement  
Administration.*

[FR Doc. 2012-12381 Filed 5-21-12; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances, Notice of Application, Alltech Associates, Inc.

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 19, 2012, Alltech Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Methcathinone (1237) .....	I
N-Ethylamphetamine (1475) .....	I
N,N-Dimethylamphetamine (1480) .....	I
4-Methylaminorex (cis isomer) (1590) .....	I
Alpha-ethyltryptamine (7249) .....	I
Lysergic acid diethylamide (7315) .....	I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348) .....	I
Tetrahydrocannabinols (7370) .....	I
Mescaline (7381) .....	I
4-Bromo-2,5-dimethoxy-amphetamine (7391) .....	I
4-Bromo-2,5-dimethoxyphenethylamine (7392) .....	I
4-Methyl-2,5-dimethoxy-amphetamine (7395) .....	I
2,5-Dimethoxyamphetamine (7396) .....	I
2,5-Dimethoxy-4-ethylamphetamine (7399) .....	I
3,4-Methylenedioxyamphetamine (7400) .....	I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402) .....	I
3,4-Methylenedioxy-N-ethylamphetamine (7404) .....	I
3,4-Methylenedioxymethamphetamine (7405) .....	I
4-Methoxyamphetamine (7411) .....	I
Alpha-methyltryptamine (7432) .....	I
Bufotenine (7433) .....	I
Diethyltryptamine (7434) .....	I
Dimethyltryptamine (7435) .....	I
Psilocybin (7437) .....	I
Psilocyn (7438) .....	I
5-Methoxy-N,N-diisopropyltryptamine (7439) .....	I
N-Ethyl-1-phenylcyclohexylamine (7455) .....	I
1-(1-Phenylcyclohexyl)pyrrolidine (7458) .....	I
1-[1-(2-Thienyl)-cyclohexyl]piperidine (7470) .....	I
Dihydromorphine (9145) .....	I
Heroin (9200) .....	I
Normorphine (9313) .....	I
Methamphetamine (1105) .....	II
1-phenylcyclohexylamine (7460) .....	II
Phencyclidine (7471) .....	II

Drug	Schedule
Phenylacetone (8501) .....	II
1-piperidinocyclohexanecarbonitrile (8603) .....	II
Cocaine (9041) .....	II
Codeine (9050) .....	II
Dihydrocodeine (9120) VII .....	
Ecgonine (9180) .....	II
Meperidine intermediate-B (9233) .....	II
Noroxymorphone (9668) VII .....	

The company plans to manufacture high purity drug standards used for analytical applications only in clinical, toxicological, and forensic laboratories.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than July 23, 2012.

Dated: May 15, 2012.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of  
Diversion Control, Drug Enforcement  
Administration.*

[FR Doc. 2012-12379 Filed 5-21-12; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF LABOR

### Approval of Information Collection Requirements; Comment Request

**AGENCY:** Office of Federal Contract Compliance Programs, Labor.

**ACTION:** Notice.

**SUMMARY:** The Department of Labor, as part of its continuing effort to reduce paperwork and respondent burden, conducts a pre-clearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed and continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA). 44 U.S.C. 3506(c)(2)(A). This program helps to ensure that requested data can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirements on respondents can be properly assessed. Currently, the Office of Federal Contract Compliance Programs is soliciting comments on its